Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma

被引：0
作者：
Beinfeld, Molly [1 ]
Lee, Sei [2 ]
McQueen, Brett [3 ]
Fluetsch, Noemi [1 ]
Pearson, Steven [1 ]
Ollendorf, Daniel A. [4 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80309 USA
[4] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2020年 / 27卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：1315 / 1320
页数：6
相关论文
共 50 条
  • [21] Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
    Liu, Ying
    Deng, Biping
    Hu, Bo
    Zhang, Wenqun
    Zhu, Qing
    Liu, Yang
    Wang, Shan
    Zhang, Pei
    Yang, Ying
    Yang, Junhan
    Zheng, Qinlong
    Yu, Xinjian
    Gao, Zifen
    Zhou, Chunju
    Han, Wei
    Yang, Jing
    Jin, Ling
    Tong, Chunrong
    Chang, Alex H.
    Zhang, Yonghong
    BLOOD ADVANCES, 2022, 6 (03) : 717 - 730
  • [22] Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
    Hoeynck, Brian
    Hwang, Wei-Ting
    Garfall, Alfred L.
    Susanibar-Adaniya, Sandra Patricia
    Vogl, Dan T.
    Waxman, Adam
    Stadtmauer, Edward A.
    Cohen, Adam D.
    BLOOD, 2022, 140 : 10081 - 10083
  • [23] Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
    Shahid, Sanam
    Prockop, Susan E.
    Flynn, Georgia C.
    Mauguen, Audrey
    White, Charlie O.
    Bieler, Jennifer
    Mcavoy, Devin
    Hosszu, Kinga
    Cancio, Maria I.
    Jakubowski, Ann A.
    Scaradavou, Andromachi
    Boelens, Jaap Jan
    Sauter, Craig S.
    Perales, Miguel-Angel
    Giralt, Sergio A.
    Taylor, Clare
    Chaudhari, Jagrutiben
    Wang, Xiuyan
    Riviere, Isabelle
    Sadelain, Michel
    Brentjens, Renier J.
    Kernan, Nancy A.
    O'Reilly, Richard J.
    Curran, Kevin J.
    BLOOD ADVANCES, 2025, 9 (07) : 1644 - 1657
  • [24] Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
    Liang, Zhiyu
    Li, Ping
    Kang, Liqing
    Zhou, Lili
    Xu, Yang
    Ye, Shiguang
    Du, Juan
    Li, Bing
    Wang, Yiwen
    Yu, Lei
    Qian, Wenbin
    Liang, Aibin
    BLOOD ADVANCES, 2022, 6 (01) : 293 - 296
  • [25] Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Madduri, Deepu
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Hari, Parameswaran
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Allred, Alicia
    Zudaire, Enrique
    Deraedt, William
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene J.
    Akram, Muhammad
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S422 - S423
  • [26] Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma
    Chen, Dongjian
    Wang, Xiaoxiang
    Chen, Zhi
    Jiang, Songfu
    Jiang, Hua
    Fu, Weijun
    Xiang, Fang
    Sun, Xuedong
    Du, Juan
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : E478 - E481
  • [27] Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma
    Bezverbnaya, Ksenia
    Moogk, Duane
    Cummings, Derek
    Baker, Christopher L.
    Aarts, Craig
    Denisova, Galina
    Sun, Michael
    McNicol, Jamie D.
    Turner, Rebecca C.
    Rullo, Anthony F.
    Foley, S. Ronan
    Bramson, Jonathan L.
    CYTOTHERAPY, 2021, 23 (09) : 820 - 832
  • [28] CAR T-cell therapy in refractory large B-cell lymphoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (01) : E19 - E19
  • [29] Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
    Usmani, Saad Zafar
    Berdeja, Jesus G.
    Madduri, Deepu
    Jakubowiak, Andrzej J.
    Agha, Mounzer E.
    Cohen, Adam D.
    Hari, Parameswaran
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn Chang
    Allred, Alicia Jones
    Zudaire, Enrique
    Deraedt, William
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene
    Akram, Muhammad
    Lin, Yi
    Martin, Thomas G.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
    Wang, Ying
    Li, Chunrui
    Xia, Jieyun
    Li, Ping
    Cao, Jiang
    Pan, Bin
    Tan, Xu
    Li, Hujun
    Qi, Kunming
    Wang, Xiangmin
    Shi, Ming
    Jing, Guangjun
    Yan, Zhiling
    Cheng, Hai
    Zhu, Feng
    Sun, Haiying
    Sang, Wei
    Li, Depeng
    Zhang, Xi
    Li, Zhenyu
    Zheng, Junnian
    Liang, Aibin
    Zhou, Jianfeng
    Xu, Kailin
    BLOOD ADVANCES, 2021, 5 (23) : 5290 - 5299
12345